Patient-Reported Outcomes in Autosomal Dominant Osteopetrosis: Findings from the Osteopetrosis Registry Study

Lynda E Polgreen,Eva Villa-Lopez,Liz Chen,Ziyue Liu,Amy Katz,Corinne Parks-Schenck,Marian Hart,Erik A Imel,Michael J Econs

DOI: https://doi.org/10.1210/clinem/dgae285

2024-04-25

The Journal of Clinical Endocrinology & Metabolism

Abstract:Abstract Context Autosomal dominant osteopetrosis (ADO) is a rare sclerotic bone disease characterized by impaired osteoclast activity, resulting in high bone mineral density and skeletal fragility. The full phenotype and disease burden on patients’ daily lives has not been systematically measured. Objective We developed an online registry to ascertain population-based data on the spectrum and rate of progression of disease and to identify relevant patient centered outcomes that could be used to measure treatment effects and guide the design of future clinical trials. Design Cross-sectional data from participants with osteopetrosis were collected using an online REDCap-based database. Participants Thirty-four participants with a confirmed diagnosis of ADO, aged 4-84 years. Main Outcome Measures Participants aged 18 years and older completed the PROMIS 57, participants aged 8 to 17 years completed the PROMIS Pediatric 49, and parents of participants aged <18 years completed the PROMIS Parent Proxy 49. Results Based on the PROMIS 57, relative to the general population, adults with ADO reported low physical function and low ability to participate in social roles and activities, and high levels of anxiety, fatigue, sleep problems, and pain interference. Daily pain medications were reported by 24% of the adult population. In contrast, neither pediatric participants, nor their parent proxy reported a negative impact on health-related quality of life. Conclusions Data from this registry demonstrate the broad spectrum of ADO disease severity and high impact on health-related quality of life in adults with ADO.

endocrinology & metabolism